1. WP3 Evaluation – six months report Sakari Karjalainen and Henna Degerlund
JARC General Assembly, Oct 16th, 2017
Istituto Nazionale Tumori, Milano

2. Tasks of Evaluation Main task
Main task is to verify if the project is being implemented as planned and are the objectives of the project reached.

3. Work done and encountered problems with possible causes (6 months report)
WP3 Leader Sakari Karjalainen participated the Steering Committee’s teleconference, held in June 12th.
WP3 organized the 1st Advisory Committee meeting in Helsinki, on September 3–4. Participants: Tit Albrecht, Karel van Damme, Helena Kääriäinen, Paolo Casali, Annalisa Trama, Sakari Karjalainen, Henna Degerlund.
Evaluation of JARC deliverables concerning the first year of JA.
The work plan of the Advisory Committee was accepted by the members of Advisory Committee during the Helsinki meeting.

4. Produced documents The minutes of Advisory Committee meeting
Evaluation of the WP2 deliverables (leaflet, website and dissemination strategy) as a part of the minutes of the Advisory Committee meeting (see above)
A web-based questionnaire for gathering participants’ feedback on workshops with external experts. Will be released after the General Assembly in October.

5. Next steps and proposals with possible problems/risks (up to April 2018).
The first JARC evaluation report will be ready in November 2017.
After April 2018
M18, 2nd Advisory Committee meeting will be held on Sep 2–3 in Helsinki, deadline 01/10/2018
D3.2, JARC second evaluation report, deadline 30/11/2018

6. We focus on:
Evaluation is focused on project implementation and considering the quality of project’s deliverables.

7. JARC Schedule – Deliverables

8. Deliverables, the first year (M1-M12):
WP2: Leaflet (M2), Dissemination plan (M5), Project website (M6)
WP1: Interim project report (M12)
WP3: JARC 1st evaluation raport (M13)

9. Deliverables, the second year (M13-24)
WP4: List of rare cancers, list of differences and commonalities between rare cancers registration and rare diseases registration
WP6: Report and survey on availability of clinical practice guidelines for all rare cancer families
WP7: Proposals to improve collaborative clinical trails in the EU
M22 (8/2018)
WP10: Recommendations on policy measures on rare cancers for national plans and strategies on cancers and rare diseases

10. Deliverables, the second year (M13-24)
WP1: Interim project report
WP4: Recommendations for the stadradized estimation of rare cancers indicators at the European and country level
WP5: Map / Database of expert centres and networks on rare cancers in Europe
WP6: Report on the assessment of the quality of existing clinical practice guidlines (for each family of rare cancers)
WP7: Report on standardization of clinical data and patient-centered clinical outcomes for big data optimal exploitation and connection to virtual biobanks and quality assurance
WP8: Map of available medical education resources and recommendations on their integration with ERNs
WP9: List of existing preclinical paediatric cancer models and research teams
M25 (11/2018)
WP3: JARC 2nd evaluation raport

11. The base and tools of evaluation
The evaluation is based on process, output and outcome indicators for each WP.
Tools of evaluation are
satisfaction questionnaires about project’s meetings and workshops
the professional evaluation, comments and opinion of advisory committee

12. WP3 Contact information
Cancer Society of Finland
Unioninkatu 22
FI Helsinki
Finland